Immunovant to Present Phase 1 Clinical Trial Results at 2019 American Academy of Neurology Annual Meeting

  • First poster presentation on IMVT-1401, a fully human anti-FcRn antibody given by subcutaneous injection, in healthy subjects
  • IMVT-1401 currently in Phase 2a clinical development for the treatment of myasthenia gravis

NEW YORK and BASEL, Switzerland, May 9, 2019 /PRNewswire/ – Immunovant, a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients living with debilitating autoimmune diseases, today announced that it will present the first detailed findings in healthy subjects for IMVT-1401 (formerly RVT-1401) in a poster session at the 2019 American Academy of Neurology (AAN) Annual Meeting, being held May 4-10, 2019, at the Pennsylvania Convention Center in Philadelphia, PA.

The online abstract for this research is available in the “Abstracts & Awards” section of the AAN Annual Meeting website, and details for the poster presentation are as follows:

Abstract Title: RVT-1401, a Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Serum IgG Following Subcutaneous or Intravenous Administration (Program Number: P5.2-079)
Poster Session Name: P5: Immunotherapies: New Targets and Side Effects
Presentation Date & Time: Thursday, May 9, 2019, 11:30 AM – 6:30 PM EDT
Location: Pennsylvania Convention Center, Philadelphia, PA

About IMVT-1401
IMVT-1401 is a novel, fully human monoclonal antibody being investigated for the treatment of IgG-mediated autoimmune diseases. IMVT-1401 is the product of a multi-step, multi-year research program, conducted by Immunovant’s collaboration partner, HanAll BioPharma, to design a highly specific anti-FcRn antibody optimized for delivery as a subcutaneous injection. These efforts have resulted in a product candidate that has been dosed at small volumes and with a small gauge needle. Immunovant intends to develop IMVT-1401 for debilitating autoimmune diseases in which there is robust evidence that pathogenic IgG antibodies drive disease manifestation and in which reduction of IgG antibodies should lead to clinical benefit. Immunovant has in-licensed the rights to develop, manufacture and commercialize IMVT-1401 in the United States, Canada, Mexico, the EU, the United Kingdom, Switzerland, the Middle East, North Africa and Latin America. IMVT-1401 presently is in Phase 2a clinical development for the treatment of myasthenia gravis (ClinicalTrials.gov Identifier: NCT03863080).

About Immunovant
Immunovant, a member of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing innovative therapies that are designed to not only treat the symptoms, but also modify the course, of autoimmune diseases. Immunovant’s lead program is IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody in development for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

About Roivant Sciences
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. Roivant does this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization.